贝伐单抗联合FOLFOIRI方案治疗晚期结直肠癌的临床研究

目的观察贝伐单抗(bevacizumab)联合FOLFOIRI方案(伊立替康180mg/m2静脉滴注d 1,联合四氢叶酸/5-氟尿嘧啶)治疗晚期结直肠癌的疗效和安全性。方法将42例晚期结直肠癌患者分为实验组和对照组,实验组21例采用贝伐单抗联合FOLFOIRI方案,用贝伐单抗5 mg/kg静滴,第1天;伊立替康(180 mg/m2)静滴,第2天;亚叶酸钙(400 mg/m2)静滴,第2天;替加氟(400 mg/m2)静滴,第2天;替加氟(2400 mg/m2)第2天,微量泵泵入,持续46h,每21 d为1周期。对照组21例采用FOLFOIR方案,除不用贝伐单抗外,其它药物及剂量和方法同试验组。完成4周期后评价疗效。结果其中39例可评价疗效和毒性。试验组总有效率为65.0%,中位生存时间(TTP)为10.6个月,对照组总有效率为31.6%,TTP为7.4个月。试验组最常见的毒副反应主要有高血压、肝功能损害、出血、骨髓抑制和胃肠道反应。结论贝伐单抗联合FOLFOI方案治疗晚期结直肠癌的疗效可靠,毒副反应可以耐受。

Study on efficacy of bevacizumab combined FOLFOIRI regimen in treatment of advanced colorectal cancer

Objective To explore the efficacy and safety of short-term bevacizumab combined FOLFOIRI regimen in treatment of advanced colorectal cancer.Methods A total of 42 patients with advanced colorectal cancer were randomly divided into bevacizumab combined FOLFOIRI regimen group（n=21） and FOLFOIRI regimen group（n=21）.Among them,39 patients received at least four courses of chemotherapy.Results The response rate（RR） was 65% in bevacizumab combined FOLFOIRI regimen group and it was 31.6% in FOLFOIRI regimen group,and their difference was significant（P0.05）.The side effects in these two groups including hypertension,bone marrow depression,gastrointestinal reactions and bleeding,and there was no significant difference between these 2 groups（P0.05）.Conclusion The efficacy of bevacizumab combined FOLFOIRI regimen in treatment of patients with advanced colorectal cancer is reliable,and their side effects were tolerable.